Medical Oncology

, Volume 16, Issue 2, pp 110–118 | Cite as

Transforming growth factor-β and multidrug resistance in chronic lymphocytic leukemia

  • William R Friedenberg
  • Sherry A Salzman
  • Sonja M Phan
  • James K Burmester
Original Paper


Patients with chronic lymphocytic leukemia (CLL) frequently respond to initial treatment, but then become resistant to chemotherapy. Studies have shown one important cause of chemotherapeutic resistance to be multidrug resistance (MDR). To investigate the potential role of MDR and transforming growth factor-β (TFG-β), a potent growth inhibitor of B lymphocytes, in the development of chemotherapeutic resistance in CLL, we evaluated 22 CLL patients for loss or mutation of TGF-β receptors (TβR), plasma TGF-β1 levels, and expression of MDR1 mRNA. Receptor crosslinking and immunoprecipitation experiments did not demonstrate loss of TβRs in any patients studied. No relationship between plasma TGF-β1 levels and expression of MDR1 mRNA was seen. Correlation of plasma TGF-β1 levels to disease stage revealed a consistent decline in plasma TGF-β1 levels with advancing disease stage (P=0.031).


receptor crosslinking growth factors plasma levels blood disease 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Sporn MB, Roberts AB. Transforming growth factor-β: recent progress and new challenges.J Cell Biol 1992;119: 1017.PubMedCrossRefGoogle Scholar
  2. 2.
    Alexandrow MG, Moses HL. Transforming growth factor β and cell cycle regulation.Cancer Res 1995;55: 1452.PubMedGoogle Scholar
  3. 3.
    Bursch Wet al. Transforming growth factor-β1 as a signal for induction of cell death by apoptosis.Br J Cancer 1993;67: 531.PubMedGoogle Scholar
  4. 4.
    Douglas RS, Capocasale RJ, Lamb RJ, Nowell PC, Moore JS. Chronic lymphocytic leukemia B cells are resistant to the apoptotic effects of transforming growth factor-β.Blood 1997;89: 941.PubMedGoogle Scholar
  5. 5.
    Fynan TM, Reiss M. Resistance to inhibition of cell growth by transforming growth factor-β and its role in oncogenesis.Crit Rev Oncol 1993;4: 493.Google Scholar
  6. 6.
    Glick AB, Weinberg WC, Wu I-H, Quan W, Yuspa SH. Transforming growth factor β1 suppresses genomic instability independent of a G arrest,p53 and Rb.Cancer Res 1996;56: 3645.PubMedGoogle Scholar
  7. 7.
    Hopkin K. The TGF-β signaling pathway: a new model with no middle.J NIH Res 1994;6: 40.Google Scholar
  8. 8.
    Markowitz SD, Roberts AB. Tumor suppressor activity of the TGF-β pathway in human cancers.Cytokine Growth Factor Rev 1996;7: 93.PubMedCrossRefGoogle Scholar
  9. 9.
    Marx J. DNA repair defect tied to mutated TGF-β receptor gene.Science 1995;268: 1276.PubMedCrossRefGoogle Scholar
  10. 10.
    Massagué Jet al. Transforming growth factor-β.Cancer Surv 1992;12: 81.PubMedGoogle Scholar
  11. 11.
    McCartney-Francis NL, Wahl SM. Transforming growth factor β: a matter of life and death.J Leukoc Biol 1994;55: 401.PubMedGoogle Scholar
  12. 12.
    Serra R, Moses HL. Tumor suppressor genes in the TGF-β signaling pathway?Nat Med 1996;2: 390.PubMedCrossRefGoogle Scholar
  13. 13.
    Teicher BAet al. Reversal ofin vivo drug resistance by the transforming growth factor-β inhibitor decorin.Int J Cancer 1997;71: 49.PubMedCrossRefGoogle Scholar
  14. 14.
    Teicher BA, Holden SA, Ara G, Chen G. Transforming growth factor-β inin vivo resistance.Cancer Chemother Pharmacol 1996;37: 601.PubMedCrossRefGoogle Scholar
  15. 15.
    Urashima Met al. Transforming growth factor-β1: differential effects on multiple myeloma versus normal B cells.Blood 1996;87: 1928.PubMedGoogle Scholar
  16. 16.
    Utsunomiya Y, Hasegawa H, Yanagisawa K, Fujita S. Enhancement ofmdr1 gene expression by transforming growth factor-β1 in the new adriamycin-resistant human leukemia cell line ME-F2/ADM.Leukemia 1997;11: 894.PubMedCrossRefGoogle Scholar
  17. 17.
    Kehrl JHet al. Transforming growth factor beta is an important immunomodulatory protein for human B lymphocytes.J Immunol 1986;137: 3855.PubMedGoogle Scholar
  18. 18.
    Kehrl JHet al. Further studies of the role of transforming growth factor-beta in human B cell function.J Immunol 1989;143: 1868.PubMedGoogle Scholar
  19. 19.
    Israels LGet al. Role of transforming growth factor-β in chronic lymphocytic leukemia.Leukemia Res 1993;17: 81.CrossRefGoogle Scholar
  20. 20.
    Lotz M, Ranheim E, Kipps TJ. Transforming growth factor β as endogenous growth inhibitor of chronic lymphocytic leukemia B cells.J Exp Med 1994;179: 999.PubMedCrossRefGoogle Scholar
  21. 21.
    Markowitz Set al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability.Science 1995;268: 1336.PubMedCrossRefGoogle Scholar
  22. 22.
    Kakeji Y, Teicher BA. Induction of transforming growth factor-β (TGF-β) by cytotoxic anticancer therapies and its potential role in the development of therapeutic resistance.Proc Am Assoc Cancer Res 1996;37: 35.Google Scholar
  23. 23.
    DeCoteau JFet al. Loss of functional cell surface transforming growth factor β (TGF-β) type 1 receptor correlates with insensitivity to TGF-β in chronic lymphocytic leukemia.Proc Natl Acad Sci USA 1997;94: 5877.PubMedCrossRefGoogle Scholar
  24. 24.
    Yasumi Ket al. Transforming growth factor β type II receptor (TGFβRII) mutation in gastric lymphoma without mutator phenotype.Pathol Int 1998;48: 134–137.PubMedCrossRefGoogle Scholar
  25. 25.
    Amoroso SR, Huang N, Roberts AB, Potter M, Letterio JJ. Consistent loss of functional transforming growth factor β receptor expression in murine plasmacytomas.Proc Natl Acad Sci USA 1998;95: 189–194.PubMedCrossRefGoogle Scholar
  26. 26.
    De Met al. Functional characterization of transforming growth factor β type II receptor mutants in human cancer.Cancer Res 1998;58: 1986–1992.PubMedGoogle Scholar
  27. 27.
    Pasche Bet al. Type I transforming growth factor β receptor maps to 9q22 and exhibits a polymorphism and a rare variant within a polyalanine tract.Cancer Res 1998;58: 2727–2732.PubMedGoogle Scholar
  28. 28.
    Cumber PMet al. Expression of the multiple drug resistance gene (MDR-1) and epitope masking in chronic lymphatic leukaemia.Br J Haematol 1990;76: 226.PubMedGoogle Scholar
  29. 29.
    El Rouby Set al. P53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent ofMDR1/MDR3 gene expression.Blood 1993;82: 3452.PubMedGoogle Scholar
  30. 30.
    Friedenberg WRet al. Multi-drug resistance in chronic lymphocytic leukemia.Leuk Lymph (in press).Google Scholar
  31. 31.
    Herweijer H, Sonneveld P, Baas F, Nooter K. Expression ofmdr1 andmdr3 multidrug-resistance genes in human acute and chronic leukemias and association with stimulation of drug accumulation by cyclosporine.J Natl Cancer Inst 1990;82: 1133.PubMedCrossRefGoogle Scholar
  32. 32.
    Holmes JAet al. Is theMDR1 gene relevant in chronic lymphocytic leukemia?Leukemia 1990;4: 216.PubMedGoogle Scholar
  33. 33.
    Ludescher Cet al. Activity of p-glycoprotein in B-cell chronic lymphocytic leukemia determined by a flow cytometric assay.J Natl Cancer Inst 1993;85: 1751.PubMedCrossRefGoogle Scholar
  34. 34.
    Michieli Met al. The expression of the multidrug resistance-associated glycoprotein in B-cell chronic lymphocytic leukaemia.Br J Haematol 1991;77: 460.PubMedCrossRefGoogle Scholar
  35. 35.
    Shustik C, Groulx N, Gros P. Analysis of multidrug resistance (MDR-1) gene expression in chronic lymphocytic leukaemia (CLL).Br J Haematol 1991;79: 50.PubMedGoogle Scholar
  36. 36.
    Sonneveld Pet al. High expression of the MDR3 multidrug-resistance gene in advanced-stage chronic lymphocytic leukemia.Blood 1992;79: 1496.PubMedGoogle Scholar
  37. 37.
    Sparrow RL, Hall FJ, Siregar H, Van Der Weyden MB. Common expression of the multidrug resistance marker P-glycoprotein in B-cell chronic lymphocytic leukaemia and correlation within vitro drug resistance.Leuk Res 1993;17: 941.PubMedCrossRefGoogle Scholar
  38. 38.
    Rochlitz CFet al. PCR-determined expression of theMDR1 gene in chronic lymphocytic leukemia.Ann Hematol 1992;65: 241–246.PubMedCrossRefGoogle Scholar
  39. 39.
    Wallner Jet al.MDR1 gene expression in chronic lymphocytic leukemia.Leuk Lymph 1994;13: 333–338.CrossRefGoogle Scholar
  40. 40.
    Beck WTet al. Methods to detect p-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations.Cancer Res 1996;56: 3010–3020.PubMedGoogle Scholar

Copyright information

© Stockton Press 1999

Authors and Affiliations

  • William R Friedenberg
    • 1
  • Sherry A Salzman
    • 2
  • Sonja M Phan
    • 2
  • James K Burmester
    • 2
  1. 1.Department of Hematology/OncologyMarshfield ClinicMarshfieldUSA
  2. 2.Marshfield Medical Research FoundationMarshfieldUSA

Personalised recommendations